HCPCS Level II code J1628 designates the injectable biologic guselkumab, billed per 1 mg unit. Guselkumab is a monoclonal antibody used in specialty dermatology and rheumatology care, and its accurate coding is important for claims processing, benefit determination, and tracking utilization of high-cost biologic therapies nationally. This code matters because biologic injections drive substantial specialty drug spend and require clear unitization for appropriate reimbursement and inventory management.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations, typical sites of service for administration, and common billing practices that affect claim acceptance.

Readers will find benchmarks for unit-based billing and service line classification, an overview of clinical context for guselkumab administration, and notes on common claim-level issues such as unit reporting and place-of-service alignment. The piece also summarizes how payers typically treat injectable biologics in outpatient and office-based settings and highlights operational considerations for billing teams and revenue cycle staff.

Data not available in the input is noted where applicable, and the content focuses on national-level implications rather than state-specific policy.